Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: A double-blind, randomized, placebo-controlled study

Endocrine Journal

Volumn 60, Issue 2, 2013, Pages 167-172

  Rhee, Yumie ^a   Song, Kijun ^a   Park, Seho ^a   Park, Hyung Seok ^a   Lim, Sung Kil ^a   Park, Byeong Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Alendronate; Aromatse inhibitor; Calcitriol; Combinative agent; Osteoporosis

Indexed keywords

AGENTS AFFECTING METABOLISM; AROMATASE INHIBITOR; CALCITRIOL PLUS ALENDRONIC ACID; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; HORMONE RECEPTOR; MAXMARVIL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; TREATMENT DURATION;

ALENDRONATE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CALCITRIOL; CALCIUM, DIETARY; CHOLECALCIFEROL; COLLAGEN TYPE I; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT DROPOUTS; PEPTIDES; POSTMENOPAUSE; REPUBLIC OF KOREA;

EID: 84874604166     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0283     Document Type: Article

References (16)

1. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492.
2. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53.
3. Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, et al. (2006) Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 22:1575-1585.
4. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, et al. (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733-738.
5. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, et al. (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34 Suppl 1:S3-18.
6. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, et al. (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514.
7. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, et al. (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010.
8. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, et al. (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967-975.
9. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, et al. (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342.
10. Swami S, Krishnan AV, Wang JY, Jensen K, Peng L, et al. (2011) Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo. Horm Cancer 2:190-202.
11. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D (2010) Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 151:32-42.
12. Rhee Y, Kang M, Min Y, Byun D, Chung Y, et al. (2006) Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 17:1801-1807.
13. VanderWalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139-156.
14. Okishiro M, Taguchi T, Kim SJ, Tanji Y, Shimazu K, et al. (2009) Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. J Cancer Res Clin Oncol 135:823-827.
15. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491.
16. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, et al. (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294.